Article Text

Pharmacoeconomics: friend or foe?
  1. M Drummond
  1. Correspondence to:
    Professor M F Drummond
    Centre for Health Economics, Alcuin “A” Block, University of York, Heslington, York YO10 5DD, UK; md18{at}


The financial constraints faced by most health systems today make it necessary for manufacturers of new, expensive drugs to demonstrate value for money. This paper describes the different types of economic evaluation; the increasing use of these analysis in decision making; their application to new drugs in the field of in rheumatoid arthritis; and the pros and cons of pharmacoeconomics studies from the perspective of the patients, the physicians, and the general population.

  • CBA, cost-benefit analysis
  • CEA, cost-effectiveness analysis
  • CUA, cost-utility analysis
  • PABC, Pharmaceutical Benefits Advisory Committee
  • QALY, quality adjusted life year
  • TNF, tumour necrosis factor
  • pharmacoeconomics
  • healthcare resources
  • economic evaluation

Statistics from


  • Competing interests: none declared

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.